IPH5201 as monotherapy or in combination with durvalumab +/- oleclumab in participants with advanced solid tumors.

Exclusion Criteria

• • Receipt of any conventional or investigational anticancer therapy (anti-cytotoxic T-lymphocyte–associated antigen 4 [anti-CTLA-4], anti-programmed cell death protein 1 [anti-PD-1], anti-programmed cell death ligand 1 [anti-PD-L1] antibodies) within 21 days of the planned first dose.
• • Receipt of agents targeting CD73, CD39, or adenosine receptors.
• • Concurrent enrollment in another therapeutic clinical study.
• • Any toxicity (excluding alopecia) from prior standard therapy that has not been completely resolved to baseline at the time of consent.
• o No toxicity leading to permanent discontinuation of prior IO therapy
• o Participants must not have required the use of additional immunosuppression other than corticosteroids
• • Active or prior documented autoimmune or inflammatory disorders within the past 5 years
• • Cardiac and vascular criteria:
• o Presence of myocardial infarction or unstable angina, or stroke, within 6 months.
• o Congestive heart failure, serious cardiac arrhythmia requiring medication, or uncontrolled hypertension
• o History of severe hypertension
• o History of any grade of blood clot within 6 months
• • Active infection, including tuberculosis; hepatitis B virus (HBV); hepatitis C virus (HCV); or human immunodeficiency virus (HIV)
• • Uncontrolled illness including certain lung diseases, uncontrolled diabetes, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study.
• • Other invasive malignancy within 2 years.
• • Major surgery within 28 days prior to first dose.
• • Female participants who are pregnant or breast feeding.